FSSAI halts Folineuro Syrup and Neuherbs True Vitamin sales over misleading claims

What to watch

• Publication of additional FSSAI enforcement orders involving supplements, vitamins, immunity products, or disease-adjacent brand names.
• Whether Global Healthfit Retail India submits its action-taken report within the stated 30-day window and whether FSSAI accepts the remediation.
• Marketplace policy changes requiring claim substantiation, revised product-category approval, or mandatory regulatory documentation.
• Additional warnings concerning the use of terms suggesting neurological, fertility, metabolic, therapeutic, or medicinal benefits in food-product branding.
• Retailer delistings, supplier recall notices, packaging redesigns, or unusual discounting in affected wellness categories.
• Consumer complaints or social-media scrutiny that expands attention from the named products to the broader supplement category.
• Immediately review product names, labels, listings, influencer copy, and search keywords for implied treatment, cure, prevention, or clinically unsupported nutrient claims.
• Pause or geo-block high-risk SKUs where product branding can be interpreted as a medicinal claim, even if the formulation is sold as a food or nutraceutical.
• Require suppliers to provide FSSAI licenses, label approvals, claim substantiation, test reports, and written indemnities before reinstating or onboarding products.
• Create a rapid delisting-and-correction workflow across ecommerce, pharmacy, distributor, and marketplace channels so removed claims do not persist in legacy listings.
• Shift merchandising toward compliant wellness cues such as ingredient transparency, recommended dietary use, and verified nutritional content rather than condition-specific benefits.
• Prepare customer-service and seller communications explaining that availability changes reflect regulatory compliance, not necessarily a product-quality finding.